R&D at the cutting edge

As a research-driven enterprise, Chiesi Group invests almost 15% of turnover in research and development in our main therapy areas: respiratory, neonatal, inflammatory and rare diseases.

This passionate commitment to innovation in terms of both active ingredients and new formulations is yielding record results, with patents being filed at a rate of one or more every working day (in 2008) and an exceptionally promising pipeline of potential new medicines.

A world class new research hub

An exciting addition to our research facilities in Italy, France, the UK and the USA is a large new state-of-the-art research in Chiesi’s birthplace of Parma.

Equipped with all the skills and technologies needed for identifying lead compounds, preclinical and clinical development and managing regulatory activities and our worldwide R&D portfolio, this sustainable, energy-efficient new facility will coordinate operations at our other international research sites in Chippenham (new drug delivery platforms), Paris (clinical research) and Rockville in Maryland (clinical and regulatory activities).